Recent news on Cytogam

CSL Favors Spending on Research Over Big Takeovers, Chief Says  -  Mar 10, 2007
BloombergCSL, which gets more than 95 percent of its earnings from plasma products, in November agreed to buy MedImmune Inc.'s CytoGam for as much as $120 million to

Product demand pushes CSL higher  -  Feb 21, 2007
The Age,In November, CSL agreed to buy MedImmune Inc's CytoGam for as much as $US120 million to widen its line of plasma treatments. CytoGam is an antibody product

CSL Ltd.: Interim Result - Strong Profit from Operations, Up 46 ...  -  Feb 21, 2007
PharmaLive.com (press release),On 9 November 2006, CSL Behring acquired the plasma product ‘CytoGam®’, a specialty immunoglobulin enriched in antibodies against cytomegalovirus.

A Shot of Income for MedImmune: Fool by Numbers  -  Feb 9, 2007
Motley FoolThe company sold its CytoGam line, recognizing a gain of $49 million, and realized gains of $42 million through the sale of two investments in its venture

MedImmune reports 4Q revenue growth  -  Feb 7, 2007
Baltimore Sun,Much of the 2006 income was attributed to the $49 million sale of MedImmune's first commercialized product, CytoGam, to another company.

CSL has dream half, lifts annual forecast  -  Feb 21, 2007
Sydney Morning Herald,Revenue included $17 million in interest earned on cash balances, which will not be repeated in the second half following the acquisition of CytoGam and

MedImmune Reports Financial Results For 2006  -  Feb 7, 2007
PR Newswire (press release),Gains on Sale of Asset and Investment Activities During the fourth quarter of 2006, MedImmune completed the sale of the CytoGam (cytomegalovirus immune

Bumper trading conditions boosting CSL  -  Feb 20, 2007
The Age,It also included $17 million in interest on earned cash balances held, which will not be repeated in the second half following the acquisition of CytoGam

CSL posts profit, lifts full-year outlook  -  Feb 20, 2007
NEWS.com.au,...period which will not be repeated in the second half following the acquisition of CytoGam and Zenyth Therapies and the settlement with Sanofi-Aventis.

MedImmune Reports Financial Results For 2006  -  Feb 7, 2007
PR Newswire (press release),During the fourth quarter of 2006, MedImmune completed the sale of the CytoGam (cytomegalovirus immune globulin intravenous (human)) product line,

MedImmune Q4 2006 Earnings Call Transcript  -  Feb 7, 2007
Seeking Alpha,In addition, we made a strategic decision to sell our CytoGam business, which resulted in a $49 million gain and may provide future gains if sales

MedImmune Posts Quarterly Profit on FluMist, Synagis (Update3)  -  Feb 7, 2007
BloombergThe company also had a gain of $49 million from the sale of CytoGam, a treatment used to boost immune systems of organ transplant patients.

Earnings Preview: Medimmune  -  Feb 5, 2007
Houston Chronicle,December turned out to be "deal month" for the company, as it closed the $50 million sale of rights to its organ transplant drug CytoGam to ZLB Behring,

MedImmune Completes Sale of CytoGam(R)  -  Dec 18, 2006
PR Newswire (press release),CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus (CMV). It is used to prevent CMV disease associated with

MedImmune finalizes $50 million sale of CytoGam  -  Dec 19, 2006
Examiner.comGaithersburg - MedImmune Inc. finalized the sale of its drug CytoGam to New Jersey-based pharmaceutical company ZLB Behring Monday.

ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin ...  -  Dec 18, 2006
American Digital Networks (press release),The acquisition includes CytoGam and related assets, including trademarks, manufacturing contracts and government authorizations associated with the product

MedImmune sells transplant drug for up to $120 million  -  Dec 19, 2006
Bizjournals.com,CytoGam, which is made from human plasma, is an intravenous immunoglobulin enriched in antibodies and used to prevent cytomegalovirus (CMV),

ZLB to pay $120M for MedImmune drug  -  Dec 19, 2006
San Antonio Business Journal,ZLB Behring completed its purchase of CytoGam, which is used to prevent infections in organ transplant patients, and related assets from MedImmune Inc. on

MedImmune Sells Drug  -  Dec 18, 2006
TheStreet.comCytoGam is an intravenous treatment containing antibodies against cytomegalovirus disease, which is often associated with transplantation of the kidney,

Medimmune sells rights to organ transplant drug  -  Dec 18, 2006
ReutersZLB Behring will pay an additional $70 million if the drug, CytoGam, meets sales targets. Medimmune said ZLB Behring has made a one-time upfront payment of

MedImmune gets license to develop asthma drug  -  Dec 19, 2006
Washington Business Journal,MedImmune (NASDAQ: MEDI) closed this week on a deal to sell its first product, transplant drug CytoGam, to ZLB Behring, a Pennsylvania biotech for $50

MedImmune completes sale of drug rights  -  Dec 18, 2006
BusinessWeekCytoGam is indicated for the prophylaxis of certain infections associated with transplantation of kidney, lung, liver, pancreas and heart, MedImmune said.

Focus today mirrors MedImmune’s past  -  Dec 7, 2006
Business Gazette,To get started quickly down the market path to revenues, the team licensed CytoGam, a drug to treat transplant infections, from Connaught Laboratories Inc.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional